Tagraxofusp

CD123 Interaction — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Tagraxofusp is a drug in the CD123 Interaction class catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as CD123 Interactions. DrugCentral lists 2 molecular targets, including EEF2 and IL3RA|CSF2RB. Recorded indications include Blastic plasmacytoid dendritic cell neoplasm.

• Drug class: CD123 Interaction; Cytotoxin.
• Mechanism of action: CD123 Interactions.
• Molecular targets: EEF2 and IL3RA|CSF2RB (2 listed in DrugCentral).
• Indications: Blastic plasmacytoid dendritic cell neoplasm.
• ATC code: L01XX67 (Other antineoplastic agents).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Blastic plasmacytoid dendritic cell neoplasm

Mechanism & targets

• Mechanism of action (MoA): CD123 Interactions
• Established pharmacologic class: CD123 Interaction; Cytotoxin

Molecular targets (2)

Target	Gene	Action	Activity
Elongation factor 2	EEF2	unknown	—
Interleukin-3 receptor	IL3RA|CSF2RB	other	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-01-07	EMA	—	STEMLINE THERAPEUTICS B.V.
2018-12-21	FDA	—	STEMLINE THERAPEEUTICS INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01XX67	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Capillary leak syndrome	789.7
Tumour lysis syndrome	94.9
Blood albumin decreased	83.5
Hypoalbuminaemia	69.3
Transaminases increased	57.3

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 2055491-00-2
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tagraxofusp used for?

DrugCentral lists the following indications for Tagraxofusp: Blastic plasmacytoid dendritic cell neoplasm.

How does Tagraxofusp work?

Tagraxofusp is classified as CD123 Interactions; its molecular targets in DrugCentral include EEF2 and IL3RA|CSF2RB.

When was Tagraxofusp first approved?

Tagraxofusp was first approved by the FDA in 2018.

What drug class does Tagraxofusp belong to?

Tagraxofusp is in the CD123 Interaction class.

Sources

• DrugCentral drug card 5323 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297573 — compound record and bioactivity
• DrugBank DB14731 — drug record
• FDA UNII 8ZHS5657EH — substance identity
• DailyMed: FDA labels for Tagraxofusp — current prescribing information (label search)
• UniProt P13639 (EEF2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.